Equol promotes rat osteoblast proliferation and differentiation through activating estrogen receptor.
Equol promotes rat osteoblast proliferation and differentiation through activating estrogen receptor.
复制标题
DOI：
10.4238/2014.july.4.21
复制
发表时间：
2014-07
期刊：
影响因子：
--
通讯作者：
J. Wang;J. Xu;B. Wang;F. Shu;K. Chen;M. Mi
中科院分区：
文献类型：
--
作者：
J. Wang;J. Xu;B. Wang;F. Shu;K. Chen;M. Mi
植物雌激素已被建议作为绝经后骨质疏松症的替代治疗方法。马酚，大豆苷元的代谢物，已被证明可以抑制去卵巢小鼠和大鼠的骨质流失。然而，雌马酚是否影响骨的形成尚未被研究。因此，我们研究了雌马酚对大鼠成骨细胞增殖和分化的影响，并探讨了其机制。不同浓度的雌马酚在培养48和72 h后显著促进成骨细胞的增殖。碱性磷酸酶（ALP）活性在雌马酚和17β-雌二醇（E2）组均显著升高，但雌马酚最低（0.01 μM）组除外。雌马酚也显著提高了骨钙素水平。雌马酚对成骨细胞增殖、ALP活性和骨钙素水平的影响被雌激素受体（ER）拮抗剂ICI182780阻断。孵育24小时后，雌马酚显著提高了成骨细胞中PKCα蛋白的表达。综上所述，我们的研究表明雌马酚可以通过激活er - pkc α相关信号通路促进大鼠成骨细胞的增殖和分化，提示雌马酚可以促进骨形成。这些结果表明雌马酚可能是治疗绝经后骨质疏松症的潜在替代药物。
Phytoestrogens have been suggested as alternative treatment for postmenopausal osteoporosis. Equol, a metabolite of daidzein, has been shown to inhibit bone loss in ovariectomized mice and rats. However, whether or not equol influences the formation of bone has not yet been investigated. Therefore, we investigated the effect of equol on the proliferation and differentiation of rat primary osteoblasts and explored the involved mechanisms. Different equol concentrations significantly promoted the proliferation of osteoblasts after 48- and 72-h incubations. The alkaline phosphatase (ALP) activity also increased significantly in all of the equol and 17β-estradiol (E2) groups, except for the lowest (0.01 μM) equol group. Equol also significantly elevated the osteocalcin levels. The effects of equol on osteoblast proliferation, ALP activity, and osteocalcin levels were blocked by the estrogen receptor (ER) antagonist ICI182780. After a 24-h incubation, the expression of protein kinase C alpha (PKCα) in osteoblasts was significantly increased by equol. In conclusion, our study demonstrated that equol could promote the proliferation and differentiation of rat osteoblasts through activating the ER-PKCα-related signaling pathway, suggesting that equol could promote bone formation. These results suggest that equol could be a potential alternative agent for the management of postmenopausal osteoporosis.